November - 2021

Nov 28, 2021

Azathioprine with Allopurinol Is a Promising First‑Line Therapy for Infammatory Bowel Diseases

Azathioprine with Allopurinol Is a Promising First‑Line Therapy for Infammatory Bowel Diseases Elsa L. S. A. van Liere, Ahmed B. Bayoumy, Chris J. J. Mulder, Ben Warner, Bu Hayee, Bilal A. Mateen, Jonathan D. Nolan, Nanne K. H. de Boer, Simon H. C. Anderson, Azhar R. Ansari Published Oct 2020, in the Digestive Diseases and Sciences. Abstract Background Benefcial response to frst-line immunosuppressive azathioprine in patients with infammatory bowel disease (IBD) is low due

eDoctor In

Nov 27, 2021

Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes

Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis Jena A, Jha DK, Kumar-M P, Kasudhan KS, Kumar A, Sarwal D, Mishra S, Singh AK, Bhatia P, Patil A, Sharma V. Published Apr 2021, in the Expert review of clinical pharmacology. Abstract Background: Prevalence and impact of thiopurine S-methyltransferase (TPMT) and Nudix hydrolase (NUDT15) minor allele frequencies in South

eDoctor In

Nov 26, 2021

Mimics of Inflammatory Bowel Disease in Clinical Practice

Mimics of Inflammatory Bowel Disease in Clinical Practice Mayank Jain Published Oct 2020, in the Tropical Gastroenterology. Case ReportMimics of Inflammatory Bowel Disease in Clinical PracticeKeywords : Mayank Jain Division of Gastroenterology, Department of Medicine, Arihant Hospital and Research Centre, Indore -452009 Corresponding Author: Dr Mayank Jain Email: mayank4670@rediffmail.com DOI: http://dx.doi.org/ There are several conditions that mimic inflammatory bowel disea

eDoctor In

Nov 25, 2021

Inflammatory bowel disease in Bahrain: single-center experienceAbdulla M, Al Saeed M, Fardan RH,

Inflammatory bowel disease in Bahrain: single-center experience Abdulla M, Al Saeed M, Fardan RH, Alalwan HF, Ali Almosawi ZS, Almahroos AF, Al Qamish J. Published Jul 2017, in the Clinical and Experimental Gastroenterology. Abstract Purpose: The number of newly diagnosed inflammatory bowel disease (IBD) cases such as ulcerative colitis (UC), Crohn's disease (CD), and indeterminate colitis (IC) is rapidly increasing in Gulf countries and Saudi Arabia. The aim of this study wa

eDoctor In

Nov 18, 2021

Epidemiology of Inflammatory Bowel Diseases in Nepal

Epidemiology of Inflammatory Bowel Diseases in Nepal Paudel MS, Khanal A, Shrestha B, Purbey B, Paudel BN, Shrestha G, Thapa J, Dewan KR, Gurung R, Published Jul 2021, in the Cureus. Abstract Introduction Inflammatory bowel diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). These are diseases of the gastrointestinal tract without a clear etiology but have strong relationships with underlying factors like genetic susceptibility, environmental factors, a

eDoctor In

Nov 18, 2021

Antibiotics for induction and maintenance of remission in ulcerative colitis: systematic review and

Antibiotics for induction and maintenance of remission in ulcerative colitis: systematic review and meta-analysis Mishra S, Jha DK, Singh AK, Kumar-M P, Patil A, Sharma V Published Oct 2021, in the Expert review of Gastroenterology & Hepatology. Abstract Objectives: To ascertain the role of antibiotics in induction and maintenance of remission in ulcerative colitis (UC) Methods: We searched electronic databases for keywords ulcerative colitis or inflammatory bowel disease and

Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach

eDoctor In

Nov 18, 2021

Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach

Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF Published Jan 2021, in the European journal of clinical pharmacology. Abstract Purpose: Infliximab (IFX) therapy in inflammatory bowel disease (IBD) is associated with loss of response in half the patients, due to complex pharmacokinetic and immunological factors. Dashboard's Bayesian algorithms use information fr

Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn's

eDoctor In

Nov 16, 2021

Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn's

Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn's disease Boparai G, Kedia S, Kandasamy D, Sharma R, Madhusudhan KS, Dash NR, Sahu P, Pal S, Sahni P, Panwar R, Vuyyuru SK, Kante B, Yadav DP, Mouli VP, Makharia G, Ahuja V Published Oct 2021, in the European journal of clinical nutrition. Abstract Background: Sarcopenia and visceral fat independently predict poor outcomes in Crohn's disease (CD). However, combined influence of these

Noninvasive Monitoring After Azathioprine Withdrawal in Patients with Inflammatory Bowel Disease

eDoctor In

Nov 14, 2021

Noninvasive Monitoring After Azathioprine Withdrawal in Patients with Inflammatory Bowel Disease

Noninvasive Monitoring After Azathioprine Withdrawal in Patients with Inflammatory Bowel Disease in Deep Remission Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S Published Oct 2021, in theClinical Gastroenterology and Hepatology. Abstract Background & aims: There is uncertainty regarding the optimal duration of treatment with azathioprine (AZA) in ulcerative colitis (UC) and Crohn's disease (CD). We analyzed the clinical course and predictors of

Impact of diagnostic delay to the clinical presentation and associated factors in pediatric IBD

eDoctor In

Nov 12, 2021

Impact of diagnostic delay to the clinical presentation and associated factors in pediatric IBD

Impact of diagnostic delay to the clinical presentation and associated factors in pediatric inflammatory bowel disease: a retrospective study Sulkanen E, Repo M, Huhtala H, Hiltunen P, Kurppa K Published Oct 2021, in the BMC Gastroenterology. Abstract Background: Undelayed diagnosis is thought to be a major determinant for good prognosis in pediatric inflammatory bowel disease (PIBD). However, factors predicting diagnostic delay and the consequences of this remain poorly defi

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment

eDoctor In

Nov 10, 2021

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment

Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease Pauwels RWM, Proietti E, van der Woude CJ, Oudijk L, Crombag MBS, Peppelenbosch MP, Grohmann U, Fuhler GM, de Vries AC Published Oct 2021, in the Inflammatory bowel diseases. Abstract Background: The association between vedolizumab (VDZ) exposure and treatment response is unclear and seems insufficiently explained by serum levels. The aim of this

eDoctor In

Nov 9, 2021

Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U

Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium Fenster M, Alayo QA, Khatiwada A, Rubin DT, Deepak P Published Oct 2021, in the Clinical gastroenterology and hepatology. Abstract The safety and efficacy of tofacitinib in Crohn's disease (CD) has been studied in 2 phase II trials in patients with moderate-to-severe CD with no new safety signals observed, but no significant difference from placebo i

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery